---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-053049"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:19:39.795336+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics announces European Commission approval of MYQORZO (aficamten) for obstructive HCM

## Summary
- European Commission approved MYQORZO (aficamten) for symptomatic obstructive HCM in adults.
- Approved dosage strengths: 5 mg, 10 mg, 15 mg, and 20 mg tablets.
- MYQORZO is an allosteric, reversible inhibitor of cardiac myosin motor activity.
- Indication covers NYHA class II-III obstructive hypertrophic cardiomyopathy.

## SEC filing metadata
- accession: 0001193125-26-053049
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000119312526053049/0001193125-26-053049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000119312526053049/cytk-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-053049
- JSON: https://secwatch.observer/filing/0001193125-26-053049.json
- Plain text: https://secwatch.observer/filing/0001193125-26-053049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.